Integra LifeSciences
IART
279 hedge funds and large institutions have $4.18B invested in Integra LifeSciences in 2023 Q1 according to their latest regulatory filings, with 24 funds opening new positions, 100 increasing their positions, 99 reducing their positions, and 22 closing their positions.
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
9% more call options, than puts
Call options by funds: $7.75M | Put options by funds: $7.14M
1% more capital invested
Capital invested by funds: $4.13B → $4.18B (+$51.8M)
1% more repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 99
0.77% more ownership
Funds ownership: 88.35% → 89.11% (+0.77%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less funds holding
Funds holding: 280 → 279 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
+$68.5M |
| 2 |
Morgan Stanley
New York
|
+$15.6M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$11.8M |
| 4 |
ClearBridge Investments
New York
|
+$9.2M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$7.57M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$52.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$45.6M |
| 3 |
Select Equity Group
New York
|
-$29.4M |
| 4 |
Millennium Management
New York
|
-$27.1M |
| 5 |
Goldman Sachs
New York
|
-$17.8M |
IART Hedge Fund Activity: Q1 2023 in Review
279 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Integra LifeSciences (IART) for Q1 2023, worth a combined $4.18B — up 1.3% from $4.13B a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new IART positions and 22 closed out — a net gain of 2 holders — while 100 added to existing stakes and 99 trimmed.
The largest buyer was Victory Capital Management, adding an estimated $68.5M. The largest seller was Janus Henderson Group, cutting an estimated $52.6M.
- 279 institutional investors held Integra LifeSciences (IART) as of Q1 2023, down from 280 in Q4 2022.
- Funds reported $4.18B of Integra LifeSciences stock for Q1 2023, up 1.3% quarter-over-quarter.
- 24 funds opened new Integra LifeSciences positions in Q1 2023 and 22 closed out, a net change of +2 holders.
- The largest Integra LifeSciences buyer in Q1 2023 was Victory Capital Management, an estimated $68.5M added.
- The largest Integra LifeSciences seller in Q1 2023 was Janus Henderson Group, an estimated $52.6M sold.
Based on aggregated 13F filings for Q1 2023.